Melanocortin receptor-specific piperazine compounds with diamine groups
    1.
    发明授权
    Melanocortin receptor-specific piperazine compounds with diamine groups 有权
    具有二胺基团的黑皮质素受体特异性哌嗪化合物

    公开(公告)号:US07968548B2

    公开(公告)日:2011-06-28

    申请号:US11464053

    申请日:2006-08-11

    IPC分类号: A61K31/495 C07D241/04

    摘要: Melanocortin receptor-specific compounds with diamine groups of the general formula and pharmaceutically acceptable salts thereof, where W is a diamine heteroatom unit with at least one cationic center, hydrogen bond donor or hydrogen bond acceptor, J, Q, L1, L2, L3, R1a, R1b, R2a, R2b and X are as defined in the specification, and the carbon atom marked with an asterisk can have any stereochemical configuration. Compounds disclosed herein bind to one or more melanocortin receptors and may be an agonist, a partial agonist, an antagonist, an inverse agonist or an antagonist of an inverse agonist as to one or more melanocortin receptors, and may be employed for treatment of one or more melanocortin receptor-associated conditions or disorders, including specifically treatment of obesity and related conditions.

    摘要翻译: 具有通式的二胺基的黑皮质素受体特异性化合物及其药学上可接受的盐,其中W是具有至少一个阳离子中心,氢键供体或氢键受体的二胺杂原子单元,J,Q,L1,L2,L3, R1a,R1b,R2a,R2b和X如本说明书中所定义,并且带有星号的碳原子可具有任何立体化学构型。 本文公开的化合物结合一种或多种黑皮质素受体,并且可以是关于一种或多种黑皮质素受体的反向激动剂的激动剂,部分激动剂,拮抗剂,反向激动剂或拮抗剂,并且可以用于治疗一种或多种黑皮质素受体 更多的黑皮质素受体相关病症或障碍,包括特别治疗肥胖症和相关病症。

    Substituted melanocortin receptor-specific single acyl piperazine compounds
    2.
    发明授权
    Substituted melanocortin receptor-specific single acyl piperazine compounds 有权
    取代的黑皮质素受体特异性单酰哌嗪化合物

    公开(公告)号:US07727991B2

    公开(公告)日:2010-06-01

    申请号:US11464051

    申请日:2006-08-11

    IPC分类号: A61K31/495 C07D295/10

    CPC分类号: C07D241/04 C07D403/12

    摘要: Melanocortin receptor-specific compounds of the general formula and pharmaceutically acceptable salts thereof, where J is a substituted or unsubstituted monocyclic or bicyclic ring structure, W is a heteroatom unit with at least one cationic center, hydrogen bond donor or hydrogen bond acceptor, Q is a substituted or unsubstituted aromatic carbocyclic ring group, L, R2a, R2b, R3a, R3b, r, x and y are as defined in the specification, and the carbon atoms marked with an asterisk can have any stereochemical configuration. Compounds disclosed herein bind to one or more melanocortin receptors and may be an agonist, a partial agonist, an antagonist, an inverse agonist or an antagonist of an inverse agonist as to one or more melanocortin receptors, and may be employed for treatment of one or more melanocortin receptor-associated conditions or disorders, including specifically treatment of obesity and related conditions.

    摘要翻译: 其中J是取代或未取代的单环或双环结构,W是具有至少一个阳离子中心,氢键给体或氢键受体的杂原子单元,Q是通式的黑皮质素受体特异性化合物及其药学上可接受的盐 取代或未取代的芳族碳环基,L,R2a,R2b,R3a,R3b,r,x和y如说明书中所定义,并且带有星号的碳原子可以具有任何立体化学构型。 本文公开的化合物结合一种或多种黑皮质素受体,并且可以是关于一种或多种黑皮质素受体的反向激动剂的激动剂,部分激动剂,拮抗剂,反向激动剂或拮抗剂,并且可以用于治疗一种或多种黑皮质素受体 更多的黑皮质素受体相关病症或障碍,包括特别治疗肥胖症和相关病症。

    Melanocortin receptor-specific piperazine and keto-piperazine compounds
    3.
    发明授权
    Melanocortin receptor-specific piperazine and keto-piperazine compounds 有权
    黑皮质素受体特异性哌嗪和酮 - 哌嗪化合物

    公开(公告)号:US07727990B2

    公开(公告)日:2010-06-01

    申请号:US11464069

    申请日:2006-08-11

    IPC分类号: A61K31/497 C07D295/067

    摘要: Melanocortin receptor-specific compounds of the general formula and pharmaceutically acceptable salts thereof, where X, W, J, Q, L1, L2, L3, R1a, R1b, R2a, and R2b are as defined in the specification, and the carbon atom marked with an asterisk can have any stereochemical configuration. Compounds disclosed herein bind to one or more melanocortin receptors and may be an agonist, a partial agonist, an antagonist, an inverse agonist or an antagonist of an inverse agonist as to one or more melanocortin receptors, and may be employed for treatment of one or more melanocortin receptor-associated conditions or disorders, including specifically treatment of obesity and related conditions.

    摘要翻译: 通式的黑皮质素受体特异性化合物及其药学上可接受的盐,其中X,W,J,Q,L1,L2,L3,R1a,R1b,R2a和R2b如本说明书中所定义, 星号可以具有任何立体化学构型。 本文公开的化合物结合一种或多种黑皮质素受体,并且可以是关于一种或多种黑皮质素受体的反向激动剂的激动剂,部分激动剂,拮抗剂,反向激动剂或拮抗剂,并且可以用于治疗一种或多种黑皮质素受体 更多的黑皮质素受体相关病症或障碍,包括特别治疗肥胖症和相关病症。